If you are wondering whether Travere Therapeutics at around US$27.82 still offers value, you are not alone, many investors are asking the same question as the stock has been on the radar of biotech ...

Travere Therapeutics’ updated fair value estimate of $42.36, up from $41.64, reflects fresh Street research that is reworking revenue growth expectations and the risk profile around the Filspari ...